Navigation Links
Joseph E. Whitters Joins MyoScience, Inc. Board of Directors
Date:6/25/2009

REDWOOD CITY, Calif., June 25 /PRNewswire/ -- MyoScience(R), Inc. today announced that Joseph E. Whitters, CPA former chairman of the board of Mentor Corporation, was elected to the MyoScience board of directors. Whitters joined the Mentor board in 2004, assuming the Chairman role soon thereafter. Mentor was acquired by Johnson and Johnson (JNJ) in 2009 for $1.1 Billion. He also serves on the boards of directors of Omnicell, Luminent Mortgage Capital, and several private companies. From 1986 to 2005, Mr. Whitters was an executive at First Health, serving as CFO for most of his tenure. During that period the company's revenues grew from $5 to $900 Million. It was acquired by Coventry Health Plans in 2005 for $1.8 Billion.

"Joe Whitters has an exceptionally strong financial and operational background. Additionally, he has a deep industry experience in the health care and aesthetics areas. This very relevant experience and his critical insight into the aesthetics market will greatly benefit a company at MyoScience's stage," said Bob Curtis, MyoScience CEO.

"I believe MyoScience has some very innovative and unique aesthetics technologies," said Whitters. "I look forward to working with this dynamic team and the board."

Whitters will fill a board seat left vacant by the stepping down of Michael Partsch, CEO of Accelemed, Inc., who has been a board member since MyoScience's initial funding. Mr. Partsch will remain a board observer.

"MyoScience has made great strides since its initial funding," said Michael Partsch. "I am honored to have been part of that success as a board member and am very excited about the opportunity available to the Company".

"Mike Partsch has been a valuable board member since our A round of financing," said Bob Curtis. "We thank him for his seminal contributions to the early success of MyoScience."

About MyoScience, Inc.

MyoScience, Inc., founded in 2005 with headquarters in Redwood City, California, is a clinical development stage company focused on developing a non-toxic treatment for dynamic facial wrinkles (frown lines between the brows and forehead and crow's feet lines). MyoScience received 510k clearance from the U.S. Food and Drug Administration for its device in 2009 for a general indication. MyoScience is currently investigating applications in aesthetics. Major investors in MyoScience, include De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures, and Medicis Capital GmbH.

    Press Contacts:
    Robert M. Curtis, President and CEO
    MyoScience, Inc.
    bcurtis@myoscience.com
    (650) 474-2600


'/>"/>
SOURCE MyoScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
2. Dr. Joseph Sweere Receives Educator of the Year Award
3. St. Josephs Hospital and Medical Center Signs Agreement for Innovative Video Conferencing Use
4. Statement by Joseph A. Califano, Jr., Chairman and Founder, The National Center on Addiction and Substance Abuse at Columbia University and Former U.S. Secretary of Health, Education, and Welfare, on New Report by the National Association of Boards of Pha
5. Joseph C. Kolars, M.D., to be U-M Medical Schools First Senior Associate Dean for Education and Global Initiatives
6. St. Josephs Healthcare System Becomes First Hospital in the Region to Implement Pre-Hospital Therapeutic Cooling to Save the Lives of Cardiac Arrest Patients
7. Statement by Joseph A. Califano, Jr., Chairman and President, The National Center on Addiction and Substance Abuse at Columbia University and Former U.S. Secretary of Health, Education and Welfare on New York States Action Council
8. Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS
9. Closing Open Heart Surgery: Saint Josephs Performs Georgias First Totally-Closed, Beating Heart Bypass Surgery
10. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
11. Fischer Medical Announces Multi-System VersaRad Installation at St. Josephs Hospital in Marshfield, WI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: